Tabriz University of Medical Sciences About    Newsletter    Contact Us    Create Account    Log in  
Advanced Pharmaceutical Bulletin
ISSN: 2228-5881      eISSN: 2251-7308  
Services
Export citation
EndNote
Reference Manager
BibTeX
Medlars
Refworks
Mendeley

Cite by
Google Scholar
PMC(0)


Article History
Submitted: 31 May 2014
Revised: 14 Jun 2014
First published online: 25 Aug 2014

Article Access Statistics
Abstract Page Views: 381
PDF Downloads: 145
Full Text Views: 0

Adv Pharm Bull. 2014;4(5):465-470 doi: 10.5681/apb.2014.069
PMID:25364664        PMCID:PMC4213787

Effects of Some Natural Immunomodulatory Compounds in Combination with Thalidomide on Survival Rate and Tumor Size in Fibrosarcoma-Bearing Mice

Original Research

Reza Aghebati Maleki 1, Dariush Shanehbandi 2, Saeed Sadigh Eteghad 3, Habib Zarredar 2, Fatemeh Zare Shahneh 2, Leili Aghebati Maleki 2, Mehrnosh Samavati 2, Hamed Asadi 1, Seyed Ehsan Mosavi 1, Afshin Habibzadeh 1, Mozhdeh Mohammadian 4, Behzad Baradaran 2 *

1 Hematology and Oncology Research Center, Tabriz University of Medical sciences, Tabriz, Iran.
2 Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
3 Neurosciences Research Center (NSRC), Tabriz University of Medical Sciences, Tabriz, Iran.
4 Amol Faculty of Paramedical Sciences, Mazandaran University of Medical Sciences, Sari, Iran.



Abstract
Purpose: Despite significant advances have been achieved in cancer therapy, response to conventional treatments like surgery, radiotherapy and chemotherapy varies among individuals. Immunotherapy is known to be an effective strategy for patients who are resistant to the currently available interventions. Methods: Ninety-six male Balb/c mice (aged 6-8 weeks) were selected and divided into twelve groups of eight. Approximately, 1×106of WEHI-164 cells were injected to each mouse for tumor genesis. Five immunotherapy treatments were considered in this study, including Heat Shock Proteins (HSP), Bacillus Calmette-Guérin (BCG), Bifidobacterium, Immuno-Modulator Drug (IMOD) and Thalidomide. After tumor formation, the groups were treated with one or more of these therapies. Tumor size and survival rate was regularly monitored.
Results: Depending on the treatment group, tumor sizes were different. In some groups, combined treatments demonstrated more inhibitory effects on tumor growth rate. The mice in group (IMOD+ Thalidomide) had the lowest survival rate but group (BCG+ HSP+ Thalidomide) survived until the end of the experiment. Conclusion: The (HSP+ BCG+ Thalidomide) group exhibited satisfactory outcomes and two third of the mice in this group went into complete remission. Some combination therapies in test groups had significant impacts on survival and tumor growth rate.






Comments
First name  
Last name  
Email address  
Comments  
Security code



This Article
PDF

Google Scholar
Articles by Aghebati Maleki R
Articles by Shanehbandi D
Articles by Eteghad SS
Articles by Zarredar H
Articles by Zare Shahneh F
Articles by Aghebati Maleki L
Articles by Samavati M
Articles by Asadi H
Articles by Mosavi SE
Articles by Habibzadeh A
Articles by Mohammadian M
Articles by Baradaran B

PubMed
Articles by Aghebati Maleki R
Articles by Shanehbandi D
Articles by Eteghad SS
Articles by Zarredar H
Articles by Zare Shahneh F
Articles by Aghebati Maleki L
Articles by Samavati M
Articles by Asadi H
Articles by Mosavi SE
Articles by Habibzadeh A
Articles by Mohammadian M
Articles by Baradaran B

Similar articles in PubMed

Share this article!

Press Manuscript Online. Powered by MAADRAYAN